Latest Distribution Partnerships News

Memphasys Limited has submitted its CE Mark application for the Felix™ sperm separation device, targeting regulatory clearance within 6-12 months to unlock the lucrative European IVF market and accelerate approvals in other key regions.

Bioxyne Limited has upgraded its FY2025 revenue guidance to approximately $28 million, driven by strong domestic performance and significant progress in European and UK markets. The company also advances its psychedelic medicines pipeline, positioning itself for sustained growth.

xReality Group is rapidly transforming its business by focusing on its high-growth Operator XR training platform, while preparing to divest legacy entertainment assets. The company reports record revenue and expanding global reach, particularly in the US defence and law enforcement sectors.

Turners Automotive Group has delivered a record FY25 profit and dividend, showcasing resilience amid economic challenges and positioning itself to exceed FY28 profit goals ahead of schedule.

Zimi Limited has paused its planned capital raising amid ongoing talks, while revealing strong operational momentum including $1.42 million in open orders and expanded market partnerships.

4DMedical has landed a significant commercial contract with Intermountain Health to deploy its FDA-cleared Pulmonary Hypertension Analysis (PHA™) product, marking a key milestone in its U.S. expansion through a strategic Microsoft-backed partnership.

Zimi Limited confirms $1.42 million in open orders with key distributor GSM Electrical, backed by shareholder approval for up to $6 million in future sales. The company also advances its commercial market ambitions through a new partnership with Zencontrol.

Volt Group Limited reported a robust 26.8% revenue increase in Q1 FY25, driven by strong performances in its EcoQuip and Wescone divisions, alongside promising advances in its ATEN Waste Heat to Power technology.

Elixinol Wellness reported a 13.7% year-on-year revenue increase in Q1 FY25, despite a softer quarter compared to record Q4, with ecommerce momentum and strategic initiatives setting the stage for margin recovery and growth in H2.

Tissue Repair Limited reports progress in its Phase 3 clinical trials for TR987® despite enrollment delays caused by US regulatory disruptions, while TR Pro+® sales hit record highs and manufacturing scale-up advances.

Orthocell has secured Health Canada approval for its nerve repair product Remplir™, adding the US$75 million Canadian market and expanding its total addressable market to US$1.8 billion. The company plans to appoint local distributors and expects first sales in H2 2025.

BauMart Holdings has unveiled a multi-pronged strategy to tackle construction labour shortages, advance green building materials, and expand mining equipment services, supported by a $482,000 rights issue.